JL1116EH - JL1116EH: Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)

Full author listing

Kerry A. Rogers (1), Xiaoxiao Lu (2), Bruno Emond (3), Zhijie Ding (2), Patrick Lefebvre (3), Marie-Hélène Lafeuille (3), Heena Mavani (2), Zaina P. Qureshi (2), Nilanjan Ghosh (4)

1) Division of Hematology, The Ohio State University, Columbus, 2)Janssen Scientific Affairs, LLC, Horsham, PA, USA, 3) Analysis Group, Inc., Montréal, QC, Canada, 4)Levine Cancer Institute, Atrium Health, Charlotte, NC